Randomized · Double-Blind · Placebo-Controlled
Among the most powerful cardiovascular improvements ever measured in a longevity supplement
In a university-run randomized clinical trial, NOVOS Core produced improvements in three key markers of vascular aging — exceeding the effect sizes reported in many studies of exercise, diet, and other supplements.
Learn about the clinical trial that set a new benchmark for longevity science
6-Month Clinical Results vs. Placebo
Three key markers. All improved.
In healthy adults aged 40+, NOVOS Core produced statistically significant improvements across three widely studied markers of cardiovascular aging biology, in a double-blind, randomized, placebo-controlled clinical study.
+2.9%
Endothelial function improvement
Flow-mediated dilation (FMD)
Improvements of ~1% in FMD are considered clinically meaningful in vascular research. By comparison, a study of aerobic exercise in a similar population improved FMD by 1.2%.
−1.18 m/s
Arterial flexibility improvement
Pulse wave velocity (PWV)
PWV typically worsens by about 1 m/s per decade of aging in adults. A 1.18 m/s improvement vs. placebo was observed after 6 months. By comparison, HIIT improved PWV by -0.63 m/s.
−6.1 mmHg
Blood pressure reduction
Systolic blood pressure (SBP) — for blood pressure already in the normal range
Epidemiological studies have found –2 mmHg in SBP is associated with meaningful differences in cardiovascular outcomes at the population level. By comparison, dietary sodium reduction reduced systolic BP by 2.4 mmHg.
¹ Inaba Y et al., Int J Cardiovasc Imaging, 2010 · ² Vlachopoulos C et al., J Am Coll Cardiol, 2010 · ³ Lewington S et al., Lancet, 2002
“Taken together, improvements across endothelial function, arterial flexibility, and systolic blood pressure point to a coherent pattern consistent with a favorable shift in vascular aging biology.”
The Organ That Ages First
Cardiovascular aging is systemic
Your heart and vascular system are among the first organs to show measurable signs of biological aging — and the most consequential.
Why multi-endpoint results are noteworthy
Most supplement studies report changes in a single biomarker — and it’s typically not a functional marker (one that measures organ function, rather than a proxy).
In this trial, NOVOS Core was associated with improvements across all three measured functional endpoints.
The biology
Cardiovascular aging involves interacting biological processes — including oxidative stress, mitochondrial dysfunction, inflammation, and impaired nitric oxide signaling.
The signal
Observing improvements across multiple aspects of cardiovascular function simultaneously may reflect a multi-pathway approach addressing upstream biology, rather than isolated downstream effects.
The design
NOVOS Core was not designed as a cardiovascular supplement. It was formulated around the 12 biological hallmarks of aging — targeting systemic aging biology.
#1
Cardiovascular disease is the leading age-related cause of death globally
1.5–2×
More deaths annually than cancer
7+ years
Of research spanning mechanistic studies, animal models, and now a human clinical trial
“I see NOVOS as inspiring — they approach aging as a complex phenomenon, aiming at all pathways and hallmarks of aging simultaneously.”
Primary Endpoint
FMD: The study's primary endpoint
Flow-mediated dilation (FMD) measures the ability of blood vessels to expand in response to increased blood flow — a key indicator of endothelial health and vascular function.
NOVOS Core significantly improved FMD both acutely (within 1 hour) and after 6 months of daily use, while the placebo group showed no meaningful change.
Baseline
5.55%
vs 5.05% placebo
1 hour
8.95%
vs 4.85% placebo
6 months (fasted)
8.1%
vs 4.95% placebo
* p < 0.0001 vs. placebo (statistical significance)
Baseline Age Equivalence
40–60+
years
FMD levels typically observed in mid-to-late adulthood
NOVOS Age Equivalence
20–30+
years
Levels typically observed in younger adult populations
Age-equivalent ranges are descriptive comparisons based on published reference values for FMD in healthy populations (Holder et al., 2021; Maruhashi et al., 2020).
This study did not assess clinical outcomes. These results do not imply diagnosis, treatment, cure, prevention of disease, or reduction in disease risk.
Data from a double-blind, randomized, placebo-controlled clinical trial in healthy adults aged 40+. Error bars represent 95% confidence intervals.
Head-to-Head Comparisons
How NOVOS Core compares to leading interventions studied in similar populations
Results compared against published meta-analyses and randomized controlled trials of exercise, diet, and supplements in similar populations.
Sustained FMD improvement (%)
Each 1% improvement in FMD has been associated with lower future cardiovascular risk in epidemiological studies.
PWV improvement (m/s)
Arterial flexibility typically worsens by ~1 m/s per decade. NOVOS Core reversed this trajectory in 6 months.
SBP reduction (mmHg) *
These reductions occurred in adults already within the normal blood pressure range — without inducing hypotension.
Effect sizes are based on published clinical trials and meta-analyses reporting changes in similar biomarkers in adult populations. These improvements were observed in healthy adults already within normal ranges, where further improvements are typically harder to achieve.
“It has been a pleasure to watch NOVOS take a disciplined, biology-first approach, combined with a willingness to engage in rigorous evaluation rather than shortcuts, in a space that too often prioritizes hype over evidence.”
What leading scientists & MDs say
“This trial provides rare human evidence that a multi-pathway nutritional strategy can meaningfully influence cardiovascular aging biology itself. The magnitude and consistency of these effects across multiple cardiovascular endpoints is unusual for a nutritional intervention in a healthy population.”
“It's the rigorously-researched, science-backed formulations that set NOVOS apart in the longevity supplements space.”
Recognized by clinicians and institutions
The scientific approach behind NOVOS has drawn attention from physicians and health institutions worldwide.
2,000+ MDs & clinicians share NOVOS Core without compensation
“It has been a pleasure to watch NOVOS take a disciplined, biology-first approach, combined with a willingness to engage in rigorous evaluation rather than shortcuts, in a space that too often prioritizes hype over evidence.”
NOVOS products are now available at world class hospitals and wellness retailers.
In the press
“NOVOS are pioneers in consumer longevity and among the first to develop a comprehensive approach that targets 12 mechanisms of aging simultaneously.”
“A recent study places Novos Core as a leader among consumer antiaging interventions.”
“A multi-ingredient longevity supplement made by the biotechnology company NOVOS may help improve markers of cardiovascular aging.”
The clinical evidence speaks for itself
NOVOS Core is one of the only longevity supplements ever to demonstrate significant improvements across multiple validated markers of cardiovascular aging in a randomized, placebo-controlled human trial.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.